ArticleBMC infectious diseases2026
Determinants of Mpox vaccine uptake and hesitancy among healthcare workers in Port Harcourt, Nigeria.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMpox is a re-emerging zoonotic disease of global public health concern. Healthcare workers (HCWs) face elevated occupational risk and influence community vaccination behaviour, yet evidence on mpox vaccine uptake and hesitancy among Nigerian HCWs is limited. This study investigated the determinants of mpox vaccine uptake and hesitancy among HCWs in Port Harcourt, Nigeria.
methodsThis cross-sectional study involved 595 HCWs recruited using multistage sampling across healthcare facilities in Port Harcourt between March and July 2025. Data collection employed a structured, validated, self-administered questionnaire encompassing sociodemographic and vaccine-related variables. Statistical analysis involved descriptive statistics, chi-square/Fisher’s exact tests, and multivariable logistic regression analyses using GraphPad Prism 9, with statistical significance set at p ≤ 0.05.
resultsGood mpox knowledge was recorded in 58.2% of respondents, while 97.8% expressed positive attitudes towards mpox and its vaccination. Nevertheless, mpox vaccine uptake was low (8.7%), though most vaccinated HCWs were fully vaccinated (86.5%). Hesitancy was 40.8%, and 62.2% were willing to recommend vaccination. In multivariable analyses, uptake was higher among HCWs in tertiary facilities (aOR = 5.32; 95% CI: 2.42–12.90; p < 0.0001), those with formal mpox training (aOR = 2.89; 95% CI: 1.52–5.47; p = 0.0011), those who had cared for suspected/confirmed mpox patients (aOR = 2.87; 95% CI: 1.40–5.79; p = 0.0035), and HCWs vaccinated against COVID-19 (aOR = 5.23; 95% CI: 2.56–11.60; p < 0.0001). Hesitancy increased with age (aOR = 1.05; 95% CI: 1.02–1.08; p = 0.0035) but was lower among COVID-19–vaccinated HCWs (aOR = 0.46; 95% CI: 0.31–0.67; p < 0.0001) and those with good mpox knowledge (aOR = 0.50; 95% CI: 0.28–0.89; p = 0.0193). The leading barriers were safety concerns (63.7%), insufficient information (56.8%), and access constraints (43.2%). Key motivators were assurance of safety/effectiveness (70.1%), convenient access (61.2%), and official recommendations (44.0%).
conclusionsA marked knowledge–attitude–behaviour gap persists. Expanding mpox training, improving risk communication, and delivering on-site vaccination beyond tertiary centres are essential to raise uptake, curb hesitancy, and strengthen Nigerian outbreak preparedness. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.